Removing blood clots from the lungs with a catheter
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a device called the FlowTriever to remove blood clots from the lungs in people with a pulmonary embolism that is not too severe. The goal is to see if this treatment can help improve heart function and symptoms without major surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have a blood clot in your lungs (pulmonary embolism) that is causing some strain on your heart but is not immediately life-threatening
- Your blood pressure is stable (you are not in shock)
- The clot is in a main, lobar, or segmental artery of the lung (not only tiny branches)
- You can take blood thinners (heparin or an alternative)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with a severe, high-risk pulmonary embolism (blood clot in the lung). It uses a catheter device to remove the clot and help the heart work better.
This Phase 3 trial tests a catheter-based procedure to remove a lung blood clot (pulmonary embolism) and reduce strain on the heart. It may help people who have specific CT scan signs of right-heart strain.
This trial tests a device that removes blood clots from the lungs in people with a recent pulmonary embolism. It may help improve blood flow and reduce strain on the heart.
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.
This study compares different real-world treatments for a serious but stable type of blood clot in the lungs (called intermediate-high risk pulmonary embolism). It aims to see which treatments work best in everyday patients, including those with other health conditions.
Hear when a new Pulmonary Embolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.